Daiichi Sankyo notes however that Delytact is the first oncolytic virus ever approved for a primary brain cancer in any region of the world, and is also its fourth cancer product approval in the ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU ... The green light from the European Commission means that Enhertu (trastuzumab deruxtecan) can now be used for patients whose ...

Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

Von der Leyen suggested a defense alternative to NATO was needed US President Donald Trump's announcement that he planned to impose tariffs on European products to even up the trade scale “would ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 62 tables and 55 figures, this 142-page report ?Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

In the face of uncertainty about Canada’s relationship with the United States, some have been proposing an alternative path: backing away from the Americans a bit and joining the European Union.

German Chancellor Olaf Scholz on Tuesday warned that the EU will jointly retaliate if US President Donald Trump moves forward with imposing tariffs on European products. Addressing lawmakers in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...